AVIR Stock Price, Atea Pharmaceuticals Inc Quote, Chart

Market Summary

USD3.71+0.02

Market Closed

0.54%

AVIR Stock Price

View Fullscreen

AVIR RSI Chart

AVIR Valuation

Market Cap

312.3M

Price/Earnings (Trailing)

-2.3

Price/Sales (Trailing)

1.01

EV/EBITDA

-1.25

Price/Free Cashflow

-3.66

AVIR Price/Sales (Trailing)

AVIR Profitability

EBT Margin

-38.40%

Return on Equity

-24.49%

Return on Assets

-22.85%

Free Cashflow Yield

-27.35%

AVIR Fundamentals

AVIR Revenue

Revenue (TTM)

351.4M

AVIR Earnings

Earnings (TTM)

-136.0M

Earnings Growth (Yr)

-13.75%

Earnings Growth (Qtr)

-18.17%

Breaking Down AVIR Revenue

Last 7 days

-0.3%

Last 30 days

-7.2%

Last 90 days

-3.4%

Trailing 12 Months

12.1%

How does AVIR drawdown profile look like?

AVIR Financial Health

Current Ratio

18.24

AVIR Investor Care

Shares Dilution (1Y)

0.18%

Diluted EPS (TTM)

-1.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	0	0
2021	124.3M	200.0M	275.7M	351.4M
2020	0	0	0	48.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Atea Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 01, 2024	hammond janet mj	sold	-53,913	3.843	-14,029	chief development officer
Feb 01, 2024	vavricka john	sold	-45,420	3.843	-11,819	chief commercial officer
Feb 01, 2024	horga maria arantxa	sold	-60,963	3.8414	-15,870	chief medical officer
Feb 01, 2024	foster wayne	sold	-47,904	3.8394	-12,477	evp, chief accounting officer
Feb 01, 2024	corcoran andrea	sold	-60,914	3.8449	-15,843	see remarks
Feb 01, 2024	sommadossi jean-pierre	sold	-218,819	3.845	-56,910	president, ceo, and chairman
Jan 31, 2024	hammond janet mj	acquired	-	-	46,800	chief development officer
Jan 31, 2024	vavricka john	acquired	-	-	33,334	chief commercial officer
Jan 31, 2024	horga maria arantxa	acquired	-	-	41,534	chief medical officer
Jan 31, 2024	foster wayne	acquired	-	-	33,334	evp, chief accounting officer

Which funds bought or sold AVIR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-6.16	189,183	967,811	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	766	430,000	471,000	-%
Apr 24, 2024	BML Capital Management, LLC	added	1.37	5,708,970	22,368,300	14.75%
Apr 23, 2024	AMALGAMATED BANK	reduced	-60.55	-10,000	11,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	2,362	144,064	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	new	-	7,000	7,000	-%
Apr 15, 2024	Sunpointe, LLC	unchanged	-	11,824	48,250	0.05%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	226	226	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.57	308,795	14,029,100	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	75.34	612,855	1,395,920	-%

Are Funds Buying or Selling AVIR?

Are funds buying AVIR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AVIR

No. of Funds

Unveiling Atea Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ecor1 capital, llc	8.4%	6,995,861	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	8.4%	6,995,861	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	8.4%	6,995,861	SC 13G/A
Feb 13, 2024	sommadossi jean-pierre	7.1%	5,925,000	SC 13G/A
Feb 13, 2024	vanguard group inc	5.51%	4,599,710	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 07, 2024	bml investment partners, l.p.	6.7%	5,462,079	SC 13G
Feb 07, 2024	bml investment partners, l.p.	6.7%	5,462,079	SC 13G/A
Jan 24, 2024	blackrock inc.	11.3%	9,443,887	SC 13G/A
Nov 28, 2023	tang capital partners lp	4.8%	4,033,463	SC 13D/A

Recent SEC filings of Atea Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Feb 28, 2024	10-K	Annual Report
Feb 28, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Atea Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Atea Pharmaceuticals Inc News

Latest updates

Atea Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	15.9%	7.00	6.00	1.00	97.00	192	33.00	60.00	66.00	-
Operating Expenses	-15.2%	35.00	42.00	32.00	42.00	71.00	55.00	52.00	35.00	28.00
S&GA Expenses	4.4%	13.00	13.00	12.00	13.00	13.00	12.00	12.00	9.00	14.00
R&D Expenses	-23.8%	22.00	29.00	20.00	30.00	58.00	43.00	40.00	27.00	14.00
EBITDA Margin	3.0%	-0.31*	-0.32*	0.07*	0.19*	0.39*	0.14*	0.21*	0.19*	-
Income Taxes	27.4%	0.00	0.00	0.00	-	-	6.00	7.00	-	-
Earnings Before Taxes	20.8%	-27.93	-35.27	-31.21	-42.08	121	-22.09	9.00	31.00	21.00
EBT Margin	2.9%	-0.31*	-0.32*	0.07*	0.19*	0.39*	0.14*	0.21*	0.19*	-
Net Income	20.5%	-28.18	-35.47	-31.33	-42.08	117	-28.19	2.00	31.00	21.00
Net Income Margin	2.9%	-0.30*	-0.31*	0.04*	0.14*	0.34*	0.09*	0.18*	0.19*	-
Free Cashflow	46.0%	-16.12	-29.85	-21.06	-59.05	-75.43	23.00	-17.35	-16.84	319

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-2.2%	595	608	626	638	667	687	694	717	773	844	872	841	864	110	-
Current Assets	-2.1%	590	603	621	632	661	682	689	713	772	843	871	840	863	108	22.00
Cash Equivalents	4.3%	144	138	214	183	188	176	684	706	765	840	816	834	850	105	22.00
Net PPE	-7.5%	1.00	1.00	1.00	2.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	51.0%	40.00	26.00	24.00	20.00	26.00	23.00	34.00	37.00	63.00	262	274	254	316	-	-
Current Liabilities	71.4%	32.00	19.00	16.00	12.00	18.00	16.00	25.00	29.00	57.00	262	274	254	316	11.00	2.00
Shareholder's Equity	-4.6%	555	582	602	618	641	663	660	680	710	581	598	586	548	-	-
Retained Earnings	-25.0%	-195	-156	-123	-95.35	-59.88	-25.45	-17.38	14.00	56.00	-61.10	-32.91	-34.45	-65.16	-85.82	-54.21
Additional Paid-In Capital	1.6%	751	739	726	714	701	689	678	666	654	642	631	621	613	9.00	5.00
Shares Outstanding	0%	83.00	83.00	83.00	83.00	83.00	83.00	83.00	83.00	83.00	83.00	83.00	83.00	-	-	-
Float	-	-	-	284	-	-	-	537	-	-	-	1,615,148	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	-24.1%	-21,834	-17,591	-16,120	-29,850	-21,545	-21,242	-19,186	-59,009	-75,423	22,603	-17,348	-16,837	318,521	-9,481	-7,798	-4,508	-	-	-
Share Based Compensation	-1.8%	12,157	12,383	12,353	12,535	11,645	11,504	11,908	11,661	11,351	10,990	10,007	7,273	2,821	4,238	209	189	-	-	-
Cashflow From Investing	147.5%	27,771	-58,513	46,565	24,480	33,488	-486,975	-1,879	-44.00	-	-	-	-	-5.00	-15.00	-	-	-	-	-
Cashflow From Financing	-100.0%	-	92.00	-	165	-	147	-	223	142	795	57.00	471	426,218	-913	106,449	-6.00	-	-	-

AVIR Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 114,243	$ 81,936
General and administrative	49,919	48,714
Total operating expenses	164,162	130,650
Loss from operations	(164,162)	(130,650)
Interest income and other, net	29,224	11,151
Loss before income taxes	(134,938)	(119,499)
Income tax benefit (expense)	(1,018)	3,590
Net loss	(135,956)	(115,909)
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale investments	891	(684)
Comprehensive loss	$ (135,065)	$ (116,593)
Net loss per share attributable to common stockholders
Basic	$ (1.63)	$ (1.39)
Diluted	$ (1.63)	$ (1.39)
Weighted-average number of common shares - basic and diluted
Basic	83,389,750	83,245,385
Diluted	83,389,750	83,245,385

AVIR Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 143,823	$ 188,460
Marketable securities	434,283	458,249
Prepaid expenses and other current assets	12,349	14,213
Total current assets	590,455	660,922
Property and equipment, net	1,289	1,705
Restricted cash		198
Other assets	1,396	1,494
Operating lease right-of-use assets, net	1,828	2,389
Total assets	594,968	666,708
Current liabilities
Accounts payable	4,252	2,551
Accrued expenses and other current liabilities	27,364	15,206
Current portion of operating lease liabilities	760	721
Total current liabilities	32,376	18,478
Operating lease liabilities	1,642	2,403
Income taxes payable	5,758	5,255
Total liabilities	39,776	26,136
Commitments and contingencies (see Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022
Common stock, $0.001 par value; 300,000,000 shares authorized; 83,435,513 and 83,287,639 shares issued and outstanding as of December 31, 2023 and 2022	83	83
Additional paid-in capital	750,737	701,052
Accumulated other comprehensive gain (loss)	207	(684)
Accumulated deficit	(195,835)	(59,879)
Total stockholders’ equity	555,192	640,572
Total liabilities and stockholders’ equity	$ 594,968	$ 666,708

About Atea Pharmaceuticals Inc

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

CEO	Dr. Jean-Pierre Sommadossi Ph.D.
WEBSITE	https://ateapharma.com
INDUSTRY	Biotechnology
EMPLOYEES	72

Atea Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Atea Pharmaceuticals Inc? What does AVIR stand for in stocks?

AVIR is the stock ticker symbol of Atea Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Atea Pharmaceuticals Inc (AVIR)?

As of Fri Apr 26 2024, market cap of Atea Pharmaceuticals Inc is 312.25 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVIR stock?

You can check AVIR's fair value in chart for subscribers.

What is the fair value of AVIR stock?

You can check AVIR's fair value in chart for subscribers. The fair value of Atea Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Atea Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVIR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Atea Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AVIR is over valued or under valued. Whether Atea Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Atea Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVIR.

What is Atea Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, AVIR's PE ratio (Price to Earnings) is -2.3 and Price to Sales (PS) ratio is 1.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVIR PE ratio will change depending on the future growth rate expectations of investors.